PL2928890T3 - Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych - Google Patents
Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznychInfo
- Publication number
- PL2928890T3 PL2928890T3 PL13814468T PL13814468T PL2928890T3 PL 2928890 T3 PL2928890 T3 PL 2928890T3 PL 13814468 T PL13814468 T PL 13814468T PL 13814468 T PL13814468 T PL 13814468T PL 2928890 T3 PL2928890 T3 PL 2928890T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- agonist activity
- beta2 adrenergic
- receptor antagonist
- receptor agonist
- Prior art date
Links
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 title 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
- 239000000048 adrenergic agonist Substances 0.000 title 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 title 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 239000003149 muscarinic antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195898 | 2012-12-06 | ||
| EP13814468.8A EP2928890B1 (en) | 2012-12-06 | 2013-12-05 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| PCT/EP2013/075672 WO2014086927A1 (en) | 2012-12-06 | 2013-12-05 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2928890T3 true PL2928890T3 (pl) | 2018-07-31 |
Family
ID=47323977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13814468T PL2928890T3 (pl) | 2012-12-06 | 2013-12-05 | Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8980913B2 (pl) |
| EP (1) | EP2928890B1 (pl) |
| KR (1) | KR102156441B1 (pl) |
| CN (1) | CN104854105B (pl) |
| AR (1) | AR093832A1 (pl) |
| BR (1) | BR112015012746A2 (pl) |
| CA (1) | CA2893627C (pl) |
| ES (1) | ES2663878T3 (pl) |
| PL (1) | PL2928890T3 (pl) |
| RU (1) | RU2661877C2 (pl) |
| TR (1) | TR201807091T4 (pl) |
| TW (1) | TW201427977A (pl) |
| WO (1) | WO2014086927A1 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| AU2013354043C1 (en) * | 2012-12-06 | 2017-08-31 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| RU2661877C2 (ru) * | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
| EP2934594B1 (en) | 2012-12-18 | 2019-09-04 | Almirall, S.A. | Cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities . |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TWI703138B (zh) * | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| AR104828A1 (es) * | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO |
| ES2783855T3 (es) * | 2015-11-16 | 2020-09-18 | Chiesi Farm Spa | Un proceso para preparar una formulación de polvo seco que comprende un anticolinérgico, un corticoesteroide y un beta-adrenérgico |
| WO2017093208A1 (en) | 2015-12-03 | 2017-06-08 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| EP3484879B1 (en) | 2016-07-13 | 2020-12-30 | Chiesi Farmaceutici S.p.A. | Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| CN110087729B (zh) | 2016-12-14 | 2022-04-05 | 北京硕佰医药科技有限责任公司 | 一类具有季铵盐结构的双功能化合物 |
| CN110343068B (zh) * | 2018-04-04 | 2022-02-11 | 沈阳药科大学 | 2-氨基-2-喹啉基乙醇类β2-受体激动剂及其制备方法和应用 |
| WO2021114207A1 (en) * | 2019-12-13 | 2021-06-17 | Rhodia Operations | Production of benzene derivatives |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2005012I1 (no) * | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| DE60320439T2 (de) | 2002-10-11 | 2009-05-20 | Pfizer Inc. | INDOLDERIVATE ALS ß2-AGONISTEN |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| DE602004021959D1 (de) | 2003-11-21 | 2009-08-20 | Theravance Inc | Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor |
| BRPI0507041A (pt) | 2004-01-22 | 2007-06-12 | Pfizer | composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| US7538141B2 (en) | 2004-03-23 | 2009-05-26 | Alan Daniel Brown | Compounds for the treatment of diseases |
| WO2005092840A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Formamide derivatives useful as adrenoceptor |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| US7528253B2 (en) | 2004-08-16 | 2009-05-05 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| JP2008510015A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| FR2898640B1 (fr) | 2006-03-20 | 2008-04-25 | Siemens Vdo Automotive Sas | Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne |
| EP2080523A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| DK2599778T3 (en) | 2009-04-23 | 2017-06-26 | Theravance Respiratory Co Llc | Diamide compounds with muscarinic receptor antagonist and beta-2 adrenergic receptor agonist activity |
| WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| EP2718281B1 (en) | 2011-06-10 | 2015-09-09 | Chiesi Farmaceutici S.p.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| MX346559B (es) * | 2011-06-10 | 2017-03-24 | Chiesi Farm Spa | Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico. |
| RU2661877C2 (ru) * | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
| AU2013354043C1 (en) * | 2012-12-06 | 2017-08-31 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
-
2013
- 2013-12-05 RU RU2015121046A patent/RU2661877C2/ru active
- 2013-12-05 ES ES13814468.8T patent/ES2663878T3/es active Active
- 2013-12-05 TR TR2018/07091T patent/TR201807091T4/tr unknown
- 2013-12-05 BR BR112015012746A patent/BR112015012746A2/pt active Search and Examination
- 2013-12-05 EP EP13814468.8A patent/EP2928890B1/en active Active
- 2013-12-05 AR ARP130104532A patent/AR093832A1/es unknown
- 2013-12-05 CA CA2893627A patent/CA2893627C/en not_active Expired - Fee Related
- 2013-12-05 KR KR1020157013736A patent/KR102156441B1/ko not_active Expired - Fee Related
- 2013-12-05 CN CN201380063339.XA patent/CN104854105B/zh not_active Expired - Fee Related
- 2013-12-05 TW TW102144562A patent/TW201427977A/zh unknown
- 2013-12-05 PL PL13814468T patent/PL2928890T3/pl unknown
- 2013-12-05 WO PCT/EP2013/075672 patent/WO2014086927A1/en not_active Ceased
- 2013-12-06 US US14/098,662 patent/US8980913B2/en not_active Expired - Fee Related
-
2015
- 2015-01-30 US US14/609,524 patent/US9453013B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014086927A1 (en) | 2014-06-12 |
| CA2893627C (en) | 2021-09-14 |
| ES2663878T3 (es) | 2018-04-17 |
| RU2015121046A (ru) | 2017-01-13 |
| US20150139916A1 (en) | 2015-05-21 |
| US9453013B2 (en) | 2016-09-27 |
| TW201427977A (zh) | 2014-07-16 |
| US20140163066A1 (en) | 2014-06-12 |
| AR093832A1 (es) | 2015-06-24 |
| EP2928890A1 (en) | 2015-10-14 |
| BR112015012746A2 (pt) | 2017-07-11 |
| US8980913B2 (en) | 2015-03-17 |
| HK1212987A1 (zh) | 2016-06-24 |
| EP2928890B1 (en) | 2018-02-28 |
| KR102156441B1 (ko) | 2020-09-17 |
| KR20150092126A (ko) | 2015-08-12 |
| CN104854105A (zh) | 2015-08-19 |
| CN104854105B (zh) | 2017-05-17 |
| CA2893627A1 (en) | 2014-06-12 |
| RU2661877C2 (ru) | 2018-07-20 |
| TR201807091T4 (tr) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2928890T3 (pl) | Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych | |
| ZA201503965B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| ZA201309242B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| KR20180085068A (ko) | 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물 | |
| IL215554A0 (en) | Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| PT2776425T (pt) | Novos derivados de ciclo-hexilamina que possuem atividades agonista adrenérgica β2 e antagonista muscarínica m3 | |
| SMT201700022T1 (it) | NUOVI DERIVATI DELLA CICLOESILAMMINA AVENTI ATTIVITÀ DI AGONISTA β2 ADRENERGICO E ANTAGONISTA MUSCARINICO M3 | |
| ZA201705376B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| IL239118A0 (en) | New cyclohexyl and quinoclidinyl carbamate compounds with beta-2 adrenergic agonistic and m3 muscarinic antagonistic activity | |
| IL236702A0 (en) | 5–ht3 receptor antagonists |